Kalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026

Data featured in oral presentation at ENDO 2026 show that dual MC3R/MC4R activation drives weight loss, limits rebound, and preserves lean mass in obese nonhuman primates 710GO, Kalohexis' novel oral dual MC3R/MC4R agonist, is currently being evaluated in a Phase 1 clinical trial as a...